Extracellular fibrinogen binding protein, Efb, from Staphylococcus aureus as an antiplatelet agent in vivo

Summary

Staphylococcus aureus produces and secretes a protein, extracellular fibrinogen binding protein (Efb), which contributes to virulence in wound infection. We have previously shown that Efb is a potent inhibitor of platelet function in vitro. We confirm here that this is also the case in vivo. Pre-treatment with Efb resulted in a significant prolongation of bleeding time in a mouse model. Furthermore, Efb was capable of rescuing animals from death caused by the administration of potent platelet agonists. This antiplatelet effect may explain the retardation of wound healing associated with Efb in S. aureus wound infections. These results are important not only in terms of understanding S. aureus pathogenesis, and consequently identifying new treatment strategies, but also with regard to the development of potential, novel antiplatelet agents for the prevention of thrombosis.

Keywords

Bacteria - platelets - thrombosis

• References

• 1 Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol 2001; 8: 270-6.
• 2 Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-7.
• 3 Mercier RC, Rybak MJ, Bayer AS. et al. Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis. Infect Immun 2000; 68: 4699-705.
• 4 Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis 1997; 25: 951-70.
• 5 Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
• 6 Siboo IR, Cheung AL, Bayer AS. et al. Clumping factor Amediates binding of Staphylococcus aureus to human platelets. Infect Immun 2001; 69: 3120-7.
• 7 Bayer AS, Sullam PM, Ramos M. et al. Staphylococcus aureus induces platelet aggregation via a fibrinogen- dependent mechanismwhich is independent of principal platelet glycoprotein IIb/IIIa fibrinogenbinding domains. Infect Immun 1995; 63: 3634-41.
• 8 O'Brien L, Kerrigan SW, Kaw G. et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors Clf A and Clf B, the serine-aspartate repeat protein Sdr E and protein A. Mol Microbiol 2002; 44: 1033-44.
• 9 Nicolau DP, Freeman CD, Nightingale CH. et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun 1993; 61: 1593-5.
• 10 Sullam PM, Bayer AS, Foss WM. et al. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun 1996; 64: 4915-21.
• 11 Shannon O, Flock JI.. Extracellular fibrinogen binding protein, Efb, from Staphylococcus aureus binds to platelets and inhibits platelet aggregation. Thromb Haemost 2004; 91: 779-89.
• 12 Boden Wastfelt MK, Flock I J. Incidence of the highly conserved fib gene and expression of the fibrinogen- binding (Fib) protein among clinical isolates of Staphylococcus aureus. J Clin Microbiol 1995; 33: 2347-52.
• 13 Colque-Navarro P, Palma M, Soderquist B. et al. Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: clumping factor and an extracellular fibrinogen binding protein. Clin Diagn Lab Immunol 2000; 714-20.
• 14 Mamo W, Boden M, Flock JI. Vaccination with Staphylococcus aureus fibrinogen binding proteins (F_gBP_s) reduces colonisation of S. aureus in a mouse mastitis model. FEMS Immunol Med Microbiol 1994; 10: 47-53.
• 15 Palma M, Nozohoor S, Schennings T. et al. Lack of the extracellular 19-kilodalton fibrinogen-binding protein from Staphylococcus aureus decreases virulence in experimental wound infection. Infect Immun 1996; 64: 5284-9.
• 16 Palma M, Shannon O, Quezada HC. et al. Extracellular fibrinogen-binding protein, Efb, from Staphylococcus aureus blocks platelet aggregation due to its binding to the alpha- chain. J Biol Chem 2001; 276: 31691-7.
• 17 Palma M, Wade D, Flock M. et al. Multiple binding sites in the interaction between an extracellular fibrinogen- binding protein from Staphylococcus aureus and fibrinogen. J Biol Chem 1998; 273: 13177-81.
• 18 Dejana E, Callioni A, Quintana A. et al. Bleeding time in laboratory animals. II –Acomparison of different assay conditions in rats. Thromb Res 1979; 15: 191-7.
• 19 DiMinno G, Silver MJ. Mouse antithrombotic assay: Asimple method for the evaluation of antithrombotic agents in vivo . Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 1983; 225: 57-60.
• 20 Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the „magic bullet“. Nat Rev Drug Discov 2003; 2: 775-89.
• 21 Edwards R, Harding KG. Bacteria and wound healing. Curr Opin Infect Dis 2004; 17: 91-6.
• 22 Epstein FH. Cutaneous wound healing. N Engl J Med 1999; 341: 738-46.
• 23 Martin P. Wound healing –Aiming for perfect skin regeneration. Science 1997; 276: 75-81.
• 24 Kang WS, Lim IH, Yuk DY. et al. Antithrombotic activities of green tea catechins and (-)-Epigallocatechin gallate. Thromb Res 1999; 96: 229-37.
• 25 Yun-Choi HS, Pyo MK, Park KM. et al. Antithrombotic effects of YS-49 and YS-51–1-Naphthylmethylanalogs of Higenamine. Thromb Res 2001; 104: 249-55.
• 26 Katada J, Takiguchi Y, Muramatsu M. et al. The invitro and in-vivo pharmacological profiles of a platelet gycoprotein IIb/IIIa antagonist, NSL-9403. Thromb Res 1997; 88: 27-40.
• 27 Molinari A, Guarneri L, Pacei E. et al. Mouse antithrombotic assay: the effects of Ca++ channel blockers are platelet-independent. J Pharmacol Exp Ther 1987; 240: 623-7.
• 28 Hirose H, Kimura T, Okada M. et al. Antiplatelet and antithrombotic effects of a novel selective phoshodiesterase 3 inhibitor, NSP-513, in mice and rats. Japanese J Pharmacol 2000; 82: 188-98.